The company said it will seek an expanded indication for the left atrial appendage closure device after it met all safety and ...

For patients with atrial fibrillation, the use of oral anticoagulant therapy to prevent stroke is limited by the risk of bleeding. Left atrial appendage closure is considered for patients who are ...

In patients with atrial fibrillation, those assigned left atrial appendage closure had similar ischemic outcomes and better bleeding outcomes compared with those assigned oral anticoagulation, ...

Physicians wrestled with endpoint composition, low event rates, a possible difference in ischemic strokes, and more.

Boston Scientific stock tumbled Monday on mixed test results for its Watchman device in patients at risk of having a stroke.

In one of the largest studies of its kind, a trial of Boston Scientific’s small, permanent cardiac implant showed that it could potentially serve as an alternative to long-term blood thin | Boston ...

CHAMPION-AF finds left atrial appendage closure and anticoagulation therapy for atrial fibrillation about equal but raises doubts about whether the former is a true alternative.

Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinners in patients with non-valvular atrial fibrilla ...

For patients with non-valvular atrial fibrillation (AFib) who had no contraindications to taking oral anticoagulants, the use of a device to close off the left atrial appendage in the heart—a small ...

The risk is fivefold.